AstraZeneca (AstraZeneca) EV-to-EBITDA : 18.02 (As of Apr. 25, 2024)

View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AstraZeneca's enterprise value is $242,015 Mil. AstraZeneca's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $13,429 Mil. Therefore, AstraZeneca's EV-to-EBITDA for today is 18.02.

The historical rank and industry rank for AstraZeneca's EV-to-EBITDA or its related term are showing as below:

AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.33 Med: 16.72 Max: 53.39
Current: 18.02

During the past 13 years, the highest EV-to-EBITDA of AstraZeneca was 53.39. The lowest was 6.33. And the median was 16.72.

AZN's EV-to-EBITDA is ranked worse than
62.99% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.075 vs AZN: 18.02

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), AstraZeneca's stock price is $75.47. AstraZeneca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.915. Therefore, AstraZeneca's PE Ratio for today is 39.41.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

AstraZeneca EV-to-EBITDA Historical Data

The historical data trend for AstraZeneca's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca EV-to-EBITDA Chart

AstraZeneca Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

21.50

17.52

39.74

25.84

17.19

AstraZeneca Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															25.84	21.17	18.20	17.30	17.19

Competitive Comparison of AstraZeneca's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, AstraZeneca's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AstraZeneca's EV-to-EBITDA falls into.

AstraZeneca EV-to-EBITDA Calculation

AstraZeneca's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	242015.118	/	13429
	=	18.02

AstraZeneca's current Enterprise Value is $242,015 Mil.
AstraZeneca's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $13,429 Mil.

AstraZeneca (NAS:AZN) EV-to-EBITDA Explanation

AstraZeneca's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	75.47	/	1.915
	=	39.41

AstraZeneca's share price for today is $75.47.
AstraZeneca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.915.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

AstraZeneca EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AstraZeneca's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca (AstraZeneca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.